ArticleRevista da Associacao Medica Brasileira (1992)2025
Importance of 18F-fluorodeoxyglucose positron emission tomography/computed tomography heterogeneity indices in non-small cell lung cancer.
Article in Revista da Associacao Medica Brasileira (1992), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this study was to assess the relationship between metabolic tumor heterogeneity indices in patients with driver mutation-positive non-small cell lung cancer, with a particular focus on the impact of heterogeneity indices on prognostic outcomes.
methodsPatients diagnosed with metastatic small-cell lung cancer with driver mutations were included in this study. The relationship between the patients' 18F-fluorodeoxyglucose positron emission tomography/computed tomography parameters and heterogeneity indices and survival was examined.
resultsHeterogeneity index-1 values greater than 0.29 were associated with an increased likelihood of mortality (61.7% in the exitus group compared to 28% in the survivor group, p=0.006). Lower heterogeneity index-2 values were more prevalent among the exitus group, with a statistically significant difference observed between the groups (55.3% in the exitus group versus 24% in the survivor group, p=0.010). The mean overall survival time was longer in patients with low heterogeneity index-1 levels (p=0.006). The mean overall survival time was found to be similar between the heterogeneity index-2 level groups (p=0.672).
conclusion18F-fluorodeoxyglucose positron emission tomography/computed tomography metabolic tumor heterogeneity indices are an important tool for predicting the prognosis of non-small cell lung cancer patients with driver mutations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.